Super-Resolution Ultrasound of the Brain in 3D (ESRC3D)

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Cerebral Stroke

Treatments

Procedure: Transtemporal ultrasound with contrast product (Sonovue)

Study type

Interventional

Funder types

Other

Identifiers

NCT06133179

APHP230511

Details and patient eligibility

About

The goal of this proof of concept study is to determine if the visualization of the middle cerebral artery and its perforators, through 3D transtemporal ultrasound imaging, is possible thanks to an off-line analysis by 3D ultrasound localization microscopy. Visualization of these vessels would allow us to conclude on the presence, or absence, of an ischemic stroke in the region of the middle cerebral artery.

To answer the question asked, 20 participants who suffered a stroke will carry out a transtemporal ultrasound examination specifically for research in the 7 days following his stroke. The data obtained will be analyzed by the CNRS medical imaging laboratory, in order to characterize the presence of a stroke and to compare the data obtained with that of standard examinations (CT and MRI).

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient aged 18 and over
Hospitalized patient with ischemic stroke in the deep territory of the middle cerebral artery
Patient with lesion observable on MRI
Patient included between 24 hours and 7 days after the ischemic stroke
Patient with a temporal window which allows soundproofing of the polygon of Willis and the middle cerebral artery
Patient having signed free, informed and written consent
Patient affiliated to a social security system (excluding AME)

Exclusion criteria

Contralateral middle cerebral artery territory stroke or contralateral middle cerebral artery occlusion
Patient with contraindication to Doppler ultrasound with contrast (right-left shunt, severe pulmonary arterial hypertension)
Patient with hypersensitivity to the active princip of Sonovue (sulfur hexafluoride) or these excipients
Patient with uncontrolled systemic hypertension
Patient with respiratory distress syndrome
Patient under guardianship or curatorship
Pregnant or breastfeeding patient (positive blood pregnancy test during hospitalization)
Patient with damaged skin at the temporal level
Patient having presented in the 7 days preceding inclusion an acute coronary syndrome or suffering from unstable ischemic heart disease